Primary care

Continuity of care and reducing risk during transitions of care

This article considers the evidence of interventions to reduce risk during transitions of care and explains best practice for pharmacy teams.…

Pancreatic exocrine insufficiency: causes, diagnosis and treatment

An overview of the causes, diagnosis and treatments for pancreatic exocrine insufficiency, including a case study of a patient’s experience.…

Community pharmacy RSV expansion programme to be expanded four-fold

The Department of Health and Social Care said up to 200 community pharmacy sites could be commissioned to provide the respiratory syncytial virus vaccination in 2025/2026.…

NHS England increases ARRS reimbursement for pharmacists in 2025/2026

The maximum reimbursable amount for Band 7–8a pharmacists employed under the Additional Roles Reimbursement Scheme will increase to £66,972.…

NHS increases funding for inclisiran although uptake remains ‘slower than expected’

In a letter sent to colleagues, NHS England said it had increased the reimbursement fee for inclisiran from £50 to £60.…

GP practices must ensure IT systems allow pharmacy staff to record consultations, new contract says

The 2025/2026 GP contract says GP Connect must be enabled to allow pharmacy staff to send consultation details into the GP practice workflow.…

Disagreement and conflict in teams

This episode of The PJ Pod explores common causes of conflict in the pharmacy workplace and outlines how staff members and managers can avoid or resolve conflict scenarios.…

Inclisiran prescribed to 7% of expected target population in three years, NHS data reveal

Exclusive: The Royal College of General Practitioners and the British Medical Association maintain that caution should be taken when prescribing inclisiran since long-term trial data on the drug will not be available until 2026.…

PJ view: There are still reasons to be optimistic about pharmacy in 2025, despite a challenging 2024

A turbulent 2024 has left the pharmacy profession with many uncertainties, but there are still opportunities to come in 2025.…